LQDA

Liquidia is an early-commercial biopharma whose investment case turns almost entirely on the launch of YUTREPIA (an inhaled dry-powder treprostinil using its proprietary PRINT particle technology), which the FDA approved in May 2025 for both PAH and PH-ILD and which began commercialization in June 2025. The impact is already visible: FY2025 revenue surged more than tenfold (+1031%) to $158M, combining early YUTREPIA sales with profit-share on Sandoz's generic Treprostinil Injection. The net loss narrowed 46.3% to $68.9M and operating cash burn improved to -$35.7M, so the launch is rapidly closing the gap to profitability after years of losses (accumulated deficit of $626.3M).

The pipeline adds real optionality. Liquidia is advancing L606 (a twice-daily liposomal treprostinil licensed from Pharmosa) through a pivotal PH-ILD study, and is planning label-expansion trials of YUTREPIA into PH-COPD, IPF, progressive pulmonary fibrosis and systemic-sclerosis Raynaud's — each a potential incremental market in respiratory/vascular disease. The dry-powder, higher-dose delivery profile is a genuine differentiator versus existing inhaled treprostinil therapies.